Olaparib in PALB2 Advanced Pancreatic Cancer

This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.

Trial Details

NCT ID
NCT06078787
Phase
PHASE2
Sponsor
Azienda Ospedaliero-Universitaria di Modena
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Olaparib 150 MG
Locations (sample)
  • Modena, Italy|44.64783,10.92539

Key Eligibility Criteria

  • Has a histologically or cytologically confirmed pancreatic adenocarcinoma
  • Has advanced (unresectable or metastatic) pancreatic cancer by American Joint Committee on Cancer 8th Edition
  • Has documented mutation in PALB2 gene (germline or somatic) that is predicted to be deleterious or suspected deleterious.
  • Has at least one lesion (measurable) that can be accurately assessed at baseline by CT scan (or MRI, if the subject is allergic to CT contrast medi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →